Breaking News

JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

KBI’s new model aims to enhance operational efficiencies, drive strategic clarity, and accelerate innovation for global biopharma customers.

JSR Life Sciences announced that KBI Biopharma, Inc. (KBI) and Selexis SA are consolidating as one organization under the KBI Biopharma name to accelerate innovation and growth for its global biopharma customers. According to JSR, the new structure will enable integrated, seamless solutions for customers, cell line development through process development, to clinical and commercial cGMP manufacturing services for mammalian programs. The streamlined operational approach supports customers i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters